OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a report issued on Monday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

NASDAQ OPGN opened at $0.56 on Monday. OpGen has a 52-week low of $0.17 and a 52-week high of $3.84. The stock has a market cap of $7.11 million, a PE ratio of -0.09 and a beta of -0.71. The firm has a 50-day moving average of $0.57 and a 200-day moving average of $0.51.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.